Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study in Participants With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed~* Have adequate organ function~* Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment~* Part A: Must have diagnosis of cancer that is advanced or metastatic~* Part B: Must have histologically confirmed squamous cell cancer of the head and neck or must have squamous cell cancer of any tumor type~* Part C: Must have histological diagnosis of squamous cell cancer of the head and neck, histological or cytological diagnosis of squamous non-small-cell lung cancer, or histological diagnosis of Stage IIIB (N2 or N3) or Stage IV squamous cell cancer of the anus that is not curable by local therapy~* Must be available during the duration of the study and willing to follow the study procedures~* If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug~* If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding~Exclusion Criteria:~* Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment~* Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C~* Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months~* Must not have systolic blood pressure \<90 millimeters of mercury (mmHg) or recurrent symptomatic orthostatic hypotension~* Must not have a family history of long QTc syndrome or be taking drugs known to cause QTc prolongation or Torsades de Pointes~* Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome~* Must not have acute leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prexasertib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).